No profile data available.
Coya Therapeutics, Inc. (COYA) is a healthcare company in the brain and nerve treatment drugs industry, based in Houston, United States, with about 8 full-time employees.
It reported revenue of $7.95 million for fiscal year 2025, up 123.6% from fiscal year 2024, and net income of -$21.23 million. Its market capitalization was $116.12 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Coya Therapeutics reported $7.95 million in revenue for fiscal year 2025, up 123.6% from $3.55 million in fiscal year 2024.
$116.12 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Anavex Life Sciences Corp. (AVXL), Tonix Pharmaceuticals Holding Corp. (TNXP), NRx Pharmaceuticals, Inc. (NRXP), Neumora Therapeutics, Inc. (NMRA).